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Objectives: To assess the virologic and immunological response of darunavir/ritonavir plus
optimized background therapy in highly antiretroviral-experienced HIV-infected patients in
Brazil.
Methods: Prospective cohort study carried out in a tertiary center in Sao Paulo, Brazil.
Three-class  antiretroviral-experienced patients with conﬁrmed virologic failure began
darunavir/ritonavir  plus optimized background therapy (nucleoside/tide reverse trans-
criptase  inhibitors ± raltegravir ± enfuvirtide ± maraviroc) after performing a genotypic
resistance  assay. Clinical evaluation and laboratory tests were collected at baseline and at
weeks  12, 24, and 48. Multivariate analysis was performed to identify predictors of virologic
response  at 48 weeks.
Results:  Ninety-two patients were included. The median of darunavir resistant mutation was1 (range 0-6). The median genotypic sensitivity score in the optimized background therapy
was  2 (interquartile range 1-2). At week 48, 83% (95% CI: 75–90%) had an HIV RNA level <50
copies/mL  and the median CD4 cell count was 301 (interquartile range 224-445) cells/mm3.
Baseline HIV RNA >100 000 copies/mL was inversely associated with virologic success at
week  48 (HR: 0.22, 95% CI: 0.06-0.85, p = 0.028).
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Conclusions: Darunavir/ritonavir plus optimized background therapy was a highly effective
salvage regimen under clinical routine conditions in a referral center in Brazil, which is
similar to the reported in high-income countries.
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Introduction
Highly active antiretroviral therapy (HAART) coverage has
improved  dramatically in low- and middle-income countries
in  the last years.1 However, a low proportion of patients are
treated  with second-line regimens in these settings.1–3 Provi-
sion  of third or more-line of HAART is a major challenge to
the  present and future of developing countries, where there is
scarce information about salvage regimens.
Darunavir/ritonavir (DRV/r) was  approved by the Food
and  Drug Administration in June 2006 for use in treatment-
experienced patients4,5 and since 2008 was  included among
the  antiretroviral drugs available in Brazil. Efﬁcacy and safety
with  DRV/r plus optimized background therapy (OBT) in
treatment-experienced patients was  shown in the POWER
studies.6 Because of its potency, high genetic barrier and resis-
tance  proﬁle, DRV/r is a critical component of salvage regimen.
The  costs of salvage regimens are high, however, there is data
from  high-income countries showing that DRV/r with an OBT
is  cost effective compared with control protease inhibitors
(PIs)  in highly treatment-experienced patients.7,8
DRV/r is available in Brazil and other middle-income
countries, however, there is no published studies about its
efﬁcacy  in this setting.
The  aim of the present study was  to assess, in a real clinical
setting,  the efﬁcacy of DRV/r plus OBT in HIV-infected patients.
Patients  and  methods
Study  population  and  ethics  statement
This prospective observational cohort study was  carried out
at  the AIDS Clinic of the Medical School, Universidade de São
Paulo,  a tertiary teaching center in Brazil.
All consecutive HIV-infected adults who received at least
one  pill of DRV/r plus OBT between April 2008 and June 2009
were  included. Criteria for DRV/r use followed the Brazilian
National Guidelines to Antiretroviral Therapy: patients with
conﬁrmed  virologic failure in HAART use and with a baseline
genotyping showing resistance to all PIs, except DRV/r. When
all  PIs, including DRV/r were resistant, the PI with the best
genotypic proﬁle was  selected. Thus, patients with resistance
to  DRV/r could be included. The HAART was  selected on the
basis  of both the treatment history and genotyping resistance,
which  identify drug resistance-associated mutations in rele-
vant  regions of the HIV genome, after the recommendation of
a  referral physician with experience in genotyping analysis.
Clinical  evaluation and laboratory tests were collected at base-
line  and at weeks 12, 24, and 48. The laboratory adverse events
were  assessed on the basis of the World Health Organization
toxicity grading scales.9lsevier Editora Ltda.   
Laboratory  evaluations
Plasma HIV-1 viral load was measured using Versant Human
Immunodeﬁciency Virus Type 1 (HIV-1) RNA v3.0. (bDNA).
The  lower limit of detection was  50 copies/mL. CD4 count-
ing  was performed after staining fresh whole blood samples
with  labeled antibodies: CD4, CD3, CD8, and CD45 in BD
TruCOUNTTM Tubes (BD Biosciences, San Jose, CA, USA). In
those  patients who received maraviroc, virus tropism for
CCR5  co-receptor has been conﬁrmed by the phenotypic assay
Troﬁle® (Monogram Biosciences, South San Francisco, CA,
USA).  Procedures used to genotype the pol gene that cod-
iﬁes  protease and the reverse transcriptase enzymes were
available  on the Brazilian National Network for HIV Geno-
typing  (RENAGENO) website (www.aids.gov.br). We  described
the frequency of eleven speciﬁc DRV resistance-associated
mutations according to the 2009 International AIDS Society-
USA  guidelines. We calculated the genotypic sensitivity score
(GSS)  that represents the sum of genotypic sensitivities to
the  drugs in the OBT, using the Brazilian Algorithm for HIV
Resistance Interpretation – 2009 Database (www.aids.gov.br).
The following scoring system was used for the GSS: a
score  of 0 was assigned if the interpretation was  resis-
tant  and a score of 1 was  assigned if the interpretation
was sensitive. Enfuvirtide, raltegravir and maraviroc were
considered to be fully active if they had not been used pre-
viously.
Statistical  analysis
The primary endpoint was  the percentage of patients with
plasma  viral load (HIV-1 RNA) below 50 copies/mL at week 48.
The  analysis of virologic efﬁcacy considered non-completers
as  failures. The secondary endpoints were the change in CD4
cell  counts from baseline through week 48 and the severe lab-
oratory  adverse events. Categorical variables were  described
as  number (proportion) and continuous variables as median
and  range or interquartile range (IQR). Baseline differences
between patients who reached or not viral load <50 copies/mL
at  week 48 were  tested in a univariate analysis, which included
crude  odds ratios (OR), Fisher’s exact test and Yates cor-
rected  Chi-squared. Independent risk factors associated with
virological  response at week 48 were  identiﬁed in the mul-
tivariate  logistic regression analysis that included variables
with  p < 0.3 from univariate analysis. Also the Hosmer and
Lemeshow  goodness-of-ﬁt test to assess the model and Wald
test  to assess the statistical signiﬁcance of covariates were
performed. The ﬁnal models were derived after assessment
Este é um artigo Open Access sob a licença de CC BY-NC-NDfor  interaction between the relevant exposures. The value of
p  < 0.05 was  considered statistically signiﬁcant. All tests were
two-sided.  Statistical analysis was performed by SPSS 18.0
(IBM,  Chicago, IL, USA).
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Table 1 – Baseline characteristics of 92 highly
antiretroviral-experienced HIV-infected patients.
Characteristic Value (n = 92)
Age, years, median (IQR) 45 (41–49)
Gender, male, n(%) 74 (80)
HIV transmission route, n(%)
Sexual  86 (94)
IDU 3  (3)
Others 3 (3)
Hypertension 17 (19%)
Diabetes mellitus 6  (7%)
Dyslipidemia 29 (32%)
Previous opportunistic disease, n(%) 59 (64)
HCV-positive, n (%) 11 (12)
HBsAg-positive, n (%) 3 (3)
Time since HIV diagnosis, years, median (range) 13 (4–21)
Duration of ART, years, median (range) 12 (4–18)
Number of previous regimens, median (range) 9 (2–22)
Number of previous PIs, median range) 4 (1–7)
Previous use of NRTI, NNRTI and PIs 87 (95)
Previous use of fos(amprenavir), n(%) 28 (30)
Previous enfuvirtide use, n(%) 5 (5)
CD4 cell count nadir, cells/L, median (IQR) 68 (18–125)
Baseline CD4 count, cells/mL, median (IQR) 164
(48.5–256.5)
HIV RNA, log10 copies/mL, median (IQR) 4.2 (3.5–4.9)
Drug resistance-associated mutations baseline
(RENAGENO)
NRTI associated mutations, median (range) 8 (3–15)
TAMs, median (range) 3 (0–6)
TAMs 3 or greater, n(%) 79 (89)
NNRTI-associated mutations, median (range) 2 (0–12)
Major PI-associated mutations, median (range) 5 (1–10)
Interpretation of DRV genotypic proﬁle:
sensitive/intermediate/resistance 76  (83%)/13
(14%)/3 (3%)
Drug resistance-associated mutations baseline (IAS)
DRV-associated mutations, median (range) 1 (0–6)
IQR, interquartile range; IDU, intravenous drug users; DRV,
darunavir; HCV, hepatitis C virus; ART, antiretroviral therapy;
NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, nonnu-
cleoside reverse transcriptase inhibitors; PI, protease inhibitors;
IAS-USA,  International AIDS Society – USA; TAM, thymidine ana-
R
N
l
h
s
r
C
6
M
r
l
(
P
elogue mutations.
esults
inety two patients were included in this study and the base-
ine  characteristics are shown in the Table 1. All patients were
ighly  treatment-experienced with prior failure to nucleo-
ide/tide reverse transcriptase inhibitor (NRTI), nonnucleoside
everse transcriptase inhibitor (NNRTI), and PI. The median
D4  cell count nadir (IQR) was  68 (18-125) cells/mm3 and
4%  of patients presented previous opportunistic disease.
ost  patients had a long time of antiretroviral exposure and
eceived  a large number of regimens.
The baseline median CD4 (IQR) cell count and viral
oad were  164 (49-257) cells/mm3 and 4.2 log10 copies/mL
3.5-4.9), respectively. The median number (range) of major
I-associated mutations was  5 (1-10), demonstrating the
xtensive  antiretroviral agents exposure of these patients. The 1 3;1  7(1):41–47  43
median  number (range) of IAS DRV-associated mutations was
1  (0-6). Only 7 (7.6%) of the genotypes had ≥3 DRV-associated
mutations [0 mutations = 26 (28.3%); 1 mutation = 37 (40.2%); 2
mutations = 22 (23.9%); 3 mutations = 3 (3.3%); 4 mutations = 1
(1.1%); 5 mutations = 2 (2.2%); and 6 mutations = 1 (1.1%)]. The
results  of DRV genotypic evaluation using the RENAGENO algo-
rithm  were: sensitive: 76 (82.6%), intermediate resistance: 13
(14.1%),  and resistance: 3 (3.3%).
All patients were naïve to DRV/r, raltegravir, and maraviroc.
Five  (5%) patients had previously failed to enfuvirtide. DRV/r
was  combined with at least one NRTI in all patients and with
one  or more  drugs of a new class consisting of raltegravir in
66  (71.7%) cases, enfuvirtide in 55 (59.8%), and maraviroc in
8  (8.7%) of them. Tenofovir was the most frequent NRTI used
(n  = 83, 90.2%) and its genotyping evaluation were:  sensitive:
16  (17.4%), intermediate resistance: 8 (8.7%), and resistance:
68  (73.9%). The median (IQR) number of fully active drugs in
the  OBT was  2 (1-2) [GSS 1 = 31 (33.7%); GSS 2 = 54 (58.7%); GSS
3  = 7 (7.6%)]. The number and percentage of patients with one,
two,  three, and four fully active drugs in the salvage regimen
was:  7 (7.6%), 31 (33.7%), 49 (53.3%), and 5 (5.4%), respectively.
There was  no difference in the proportion of patients with
viral  load <50 copies/mL among patients with three or two
full  active drugs in the salvage regimen [OR: 0.89 (95% CI:
0.22-3.23,  P = 1.0]. After 48 weeks, 40 (81.6%) of 49 patients
with three fully active drugs and 26 (83.9%) of 31 patients
with two fully active drugs in the regimen had viral load <50
copies/mL.  The other 12 patients received one (n = 7, 7.6%) or
four  (n = 5, 5.4%) fully active drugs in the regimen. The base-
line  median CD4 (IQR) cell count was similar among patients
with  three or two full active drugs [152 (47-278) cells/mm3
versus 163 (42-258) cells/mm3, respectively (p = 0.816)]. In
addition,  the baseline median viral load was  similar among
patients  with three or two full active drugs [4.3 (3.7-4.8) log10
copies/mL versus 4.5 (3.3-5.1) log10 copies/mL, respectively
(p  = 0.778)].
The main ﬁnding of this study was the high rate of virologic
suppression with DRV/r plus OBT among highly antiretroviral-
experienced HIV-infected patients. After 48 weeks, 76 de
92  patients (82.6%, 95% CI: 74.9–90.4) had viral load <50
copies/mL. Fig. 1 shows treatment efﬁcacy during the follow-
up.
After  48 weeks, the median of the CD4  cell count (IQR)
was  301 (224-445) cells/mm3. CD4 cell count increased signiﬁ-
cantly  by a median (IQR) of 82 (26-124) cells/mm3, 108 (54-174)
cells/mm3, and 118 (52-215) cells/mm3 at weeks 12 (n = 81),
24  (n = 87), and 48 (n = 89), respectively (p < 0.0001 for all dif-
ferences  in comparison with baseline). At week 12, CD4 cell
count  was  not available in 11 patients. Two of them had died
and  in 9 (10%) cases the samples were  not collected timely. At
week  24, CD4 cell count was  not available in 5 patients. Two
of  them were  of patients who died within 12 weeks, and in 3
cases,  the samples were not collected timely. At week 48, the
three  lost samples were of patients who died, including one
after  week 24.
Three  (3.3%) patients died during the study period. The
ﬁrst  one died at day 3 of salvage regimen due to progres-
sion of steatohepatitis, cholestasis and pancreatitis caused by
cytomegalovirus and HIV. The second patient died at week 4
of salvage regimen (CD4 cell count = 110 cells/mm3 and viral
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Fig. 1 – Percentage of subjects who  achieved HIV-1 RNA
levels  <50 copies/mL through the study period. Absolute
numbers of patients with viral load <50 copies/mL: week 4:
n = 30; week 12: n = 62; week 24: n = 72; week 48: n = 76.
Vertical bars indicate 95% conﬁdence interval.
susceptibility  to DRV/r were favorable and probably inﬂuenced
the  high rates of efﬁcacy. By the contrast, the reported efﬁ-load <50 copies/mL) due to progression of Burkitt’s lymphoma,
sepsis  and intestinal perforation. The third case died at week
32  of salvage regimen (CD4 cell count = 439 cells/mm3 and viral
load  <50 copies/mL) due to acute liver failure in a prior idio-
pathic  cirrhotic patient. In this last case, death was probably
related  to salvage regimen.
Univariate  and multivariate analysis of factors associated
with  HIV RNA <50 copies/mL at 48 weeks of HAART are shown
in  the Table 2. Baseline HIV RNA >100 000 copies/mL was
inversely associated with virologic success.
All the 55 patients who  used enfuvirtide had at least one
sign  or symptom characterizing local injection site reactions.
In  most cases these reactions were mild but 6 (10.9%) patients
discontinued this drug during the study period because
presented moderate or severe reactions. Two of them had
switched  from enfuvirtide to raltegravir. All of these 6 patients
maintained a salvage regimen with two or more  fully active
drugs,  including those sensitive to DRV/r. Five of these six
patients  had viral load <50 copies/mL at week 48.
We  found grade 3-4 laboratory abnormalities in 9 (9.8%)
patients: elevated glucose level = 3 cases; elevated triglycerides
levels  = 2 cases; elevated alanine or aspartate aminotrans-
ferase level = 2 cases; and creatine phosphokinase level = 1
case.  We  observed two laboratory abnormalities that resulted
in  the tenofovir discontinuation: proximal tubulopathy in one
person and hepatotoxicity in the other one. In the last case all
drugs  (tenofovir, lamivudine, DRV/r, raltegravir and maraviroc)
were  discontinued.
Discussion
This study shows feasibility to achieve excellent virologic and
immunologic  response with DRV/r plus OBT among highly
antiretroviral-experienced HIV-infected patients under rou-
tine  clinical care in Brazil. 0 1 3;1 7(1):41–47
A recent systematic review and meta-analysis of random-
ized  controlled trials to assess the overall efﬁcacy of new
antiretroviral drugs, including DRV/r, conﬁrmed the beneﬁt
of  these drugs in treatment-experienced patients, compared
with  placebo.10
Our results should be interpreted in the context of the prior
studies  with DRV/r. Main information of selected random-
ized,  non-randomized clinical trials, and observational studies
that  evaluated DRV/r as part of a salvage regimen in HIV-
infected patients are shown in Table 3. These studies showed
the  importance of DRV/r as part of a salvage regimen.
In the present study we observed 83% of patients with viral
load  <50 copies/mL at week 48. This outcome is superior to
randomized  clinical trials6,11,12 but similar to one non ran-
domized clinical trial13 and some observational studies.14,15
Although comparisons between studies should be made with
caution  due to design issues different enrollment criteria,
patient population, time period, and composition of the reg-
imen  (Table 3), we consider that some characteristics seem
to  justify our results. All of our multi-experienced patients
were  naïve both to DRV/r and raltegravir and only 5% had
prior  failure with enfuvirtide. All received at least one drug of
a  new class (raltegravir, 72% of cases; enfuvirtide, 60% of cases;
and  maraviroc, 9% of cases), and the median (IQR) GSS in the
OBT  was  2 (1-2). Thus, 92% of patients received at least two
active  drugs, most of them including a DRV/r and a new active
drug.  In addition, most of patients (92%) showed genotypes
with  <3 DRV-associated mutations, showing viral suscepti-
bility  to this antiretroviral agent. Differential features were
observed  in randomized clinical trials and could explain, at
least  in part, the variable efﬁcacy rates. In POWER 1 and 2
studies,6 enfuvirtide was the single new drug available and
78%  of DRV/r patients showed <3 DRV resistance-associated
mutations. In BENCHMRK 1 and 2 studies,11 85% patients had
≥1  active agents in the OBT by phenotypic sensitivity score
(PSS),  and 38% and 40% of raltegravir group received enfuvir-
tide  and DRV/r, respectively. In DUET 1 and 2 studies,12 84%
patients  had ≥1 active agents in OBT by PSS. As all patients
from  both groups received DRV/r, the relatively high efﬁcacy
rate  in the placebo group is in accordance with the efﬁcacy
observed in the POWER trials.6 Our results are similar to ANRS
TRIO  Trial, a multicenter, phase II, non-comparative study,13
in which genotypic susceptibility to DRV/r and etravirine was
an  inclusion criterion and all patients were  naïve to ralte-
gravir.  This proﬁle was  fundamental to explain the high rate
of  virology success of this trial. In addition to randomized and
clinical  trials, the results of two observational studies are in
line  with the expected beneﬁt of DRV/r-based salvage regi-
mens.  In the ﬁrst,14 65% of the patients received three full
active  drugs, without taking into account the NRTIs used, and
all  patients received at least two fully active new drugs in the
regimen.  Baseline median (range) DRV resistance-associated
mutations was  1 (0-2). In the second,15 all patients received
DRV/r, etravirine and raltegravir, and baseline median (range)
DRV  resistance-associated mutations was 1 (0-3). Thus, simi-
lar  to our study, composition of the salvage regimens and viralcacy  of another observational study was  moderate.16 Some
features  could partially to explain its efﬁcacy results: the
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Table 2 – Univariate and multivariate analysis of factors associated with HIV RNA <50 copies/mL at week 48 of
antiretroviral therapy.
Univariate Multivariate
OR (crude) 95% CI p value OR (adjusted) 95% CI p value
Male gender 2.20  0.69–7.19 0.342
Age  <40 years 2.69 0.82–8.95 0.213 2.25 0.63–7.99 0.210
Previous opportunistic diseases 0.12 0.02–0.76 0.047 0.21 0.04–1.10 0.065
Duration of ART <14 years 0.13 0.01–1.02 0.054 0.16 0.19–1.39 0.097
Number of previous regimens ≥9 1.87 0.59–5.96 0.464
Previous or current use of fos (amprenavir) 1.63 0.44–5.97 0.703
Hepatitis C 0.74 0.16–3.39 1.000
Baseline CD4 ≥100 cells/mL 3.08 0.95–9.89 0.118 1.21 0.29–5.00 0.796
The lowest CD4 level ≥50 cells/mL 2.69 0.83–8.60 0.182 1.95 0.54–7.10 0.308
Baseline HIV RNA >100 000 copies/mL 0.28 0.09–0.90 0.069 0.22 0.06–0.85 0.028
Number of mutations to DRV ≤2 2.03 0.42–10.22 0.769
Number of thymidine analogue mutations ≥3 1.07 0.24–5.00 1.000
y sco
b
w
n
r
m
eART, antiretroviral therapy; DRV, darunavir; GSS, genotypic sensitivit
analysis entered.
aseline median (IQR) DRV resistance-associated mutations
as  2 (1-3), only 47% of the patients received at least one
ew  active drug and 32% of DRV/r patients showed ≥ 3 DRV
esistance-associated mutations.
Taken together, the optimal composition of salvage regi-
en  and resistance proﬁle of most of our patients seem to
xplain  the high rate of virologic suppression observed in the
Table 3 – Selected randomized, non-randomized clinical trials a
darunavir/ritonavir (DRV/r).
Randomized clinical trials
Trial name
(ARV  agent)
Number  of
patients
Comparator  ARV
regimen
POWER 1 and 2 (DRV)6 255 Placebo + OBT
(≥2  NRTI ± ENF
BENCHMRK 1 and 2 (RAL)11 699 Placebo + OBT
(≥2 NRTI ± DRV/
or  TPV/r ± ENF)
DUET 1 and 2 (ETV)12 1203 Placebo + OBT
(DRV/r  + NRTI ± E
Non-randomized clinical trial
Trial name Number of
patients
Regimen
TRIO13 103 DRV/r + E
Observational studies
Number of
patients
Regimen
Imaz et al.14 32 DRV/r + ETV + RAL
Imaz et al.15 122 At least 3 of DRV/r, E
Delaugerre et al.16 62 2 ITRN + DRV/
ARV, antiretroviral; DRV, darunavir; RAL, raltegravir; ETV, etravirine; MVQ
NRTI, nucleoside reverse-transcriptase inhibitor; IC, conﬁdence interval.
a Intention-to-treat analysis.re. Binary logistic model in which variables with p < 0.3 in univariate
present  study even similar with a rate of virologic suppression
to  that expected in treatment-naïve patients.
Most of our patients received a new scheme in accordance
with current recommendations of main international guide-
lines  to salvage regimen with at least two, and preferably three,
fully  active drugs on the basis of drug treatment history, resis-
tance  testing, or new mechanistic class.17,18
nd observational studies of salvage regimens including
Viral load <50 copies/mL at
48  weeks vs. comparator
ARV regimen, %a
p
)
45  vs. 10 <0.001
r
62 vs. 33 <0.001
NF)
60  vs. 40 <0.001
 OBT Viral load <50
copies/mL at 48
weeks,  %
TV + RAL ±NRTI ± ENF 86 (95% CI: 80-93)
 OBT Viral load <50
copies/mL, %
 None 94 (at 24-week)
TV, RAL, MVQ ±NRTI 78 (at 48-week)
r At least 1 of
RAL,  ETV or ENF
55  (at 36-week)
, maraviroc; ENF, enfuvirtide; OBT: optimized background therapy;
 i s . 246  b r a z j i n f e c t d
Several subgroup analyses identiﬁed higher CD4 cell count
and  lower viral load associated with better virologic response
in  salvage regimen.6,11,19 In this line, in the present study, only
baseline  viral load >100 000 copies/mL was  inversely related
with  viral load <50 copies/mL at week 48.
There is no information from randomized clinical trials
designed to answer the question about the use of two versus
three  full active drugs in salvage regimen. A recent systematic
review  and meta-analysis identiﬁed that the main predictive
factor  for efﬁcacy was  the number of fully active drugs.10
However, this study did not have appropriate data to eval-
uate  potential beneﬁts of a regimen with three full active
drugs.  Subgroup analyses of randomized clinical trials showed
a  trend to beneﬁt of schemes with three versus two active
drugs.6,11,12,19 In addition, published non-randomized trial
and  observational studies with three active drugs reported
very  high rates of virologic suppression.13–15 In our exploratory
analysis, differences in the proportion of patients with viral
load  <50 copies/mL among patients with three or two full
active  drugs were  not observed. Currently, it is common to
recommend  giving three fully active drugs to most patients
with  multiclass drug resistance in routine clinical practice
from  developed countries.17,18,20,21 However, it is a controver-
sial issue and an individually based approach is necessary,
also  taking into account the patient’s needs and tolerance
to  previous regimens, complexity of the salvage therapy and
costs.22 This last issue is particularly challenging in devel-
oping  countries where cost-effectiveness analyses of salvage
regimens  are awaited.
The  number of active drugs is an important component
but this variable should be always evaluated in the context of
the  drug potency and viral susceptibility.18 It is probable that
in  some subsets of patients with factors associated with viral
response  (for example, high CD4 cell counts, low basal viral
load  and/or absence of or few DRV-associated resistance muta-
tions)  a DRV/r-based salvage regimen employing only two full
active drugs might be as effective as three full active drugs.22,23
Two studies performed in Sao Paulo reported a low preva-
lence  of DRV resistance-associated mutations in HIV-infected
patients presenting virologic failure and without history of
DRV  exposure. In one, only 6% of 171 HIV-infected patients
failing  PI-based regimes showed genotypes with ≥3 DRV
resistance-associated mutations.24 In the other one, only 2%
of  2474 HIV-infected patients failing several antiretroviral
regimes showed genotypes with ≥3 DRV resistance-associated
mutations.25 These results suggested that DRV could be an
important  component of a salvage regimen in our setting and
the  present study conﬁrmed this hypothesis.
In our study, enfuvirtide was  used in 60% of cases.
Nowadays, the higher accessibility of new generation and
new  classes of drugs will prevent the extensive use of this
one.17,18,21,26
There is a concern about the cross-resistance proﬁle
between DRV and fos(amprenavir). Some studies suggested
that  prior failure27 or prior use24 of fos(amprenavir) were  asso-
ciated  with having more  DRV-speciﬁc resistance mutations
in  multivariate analysis. Nevertheless, in the present study,
previous  or current use of fos(amprenavir) was  not associ-
ated  with virologic success at week 48 of HAART. This ﬁnding
should  be considered with caution. The number of patients 0 1 3;1 7(1):41–47
included  in this study does not confer statistical power to
answer  this question. Although the results of POWER 1, 2, and
3  subgroup analyses reported that prior utilization or resis-
tance  to fos(amprenavir) at screening had only a minimal
effect  on the virologic response to DRV/r at week 48,28 this
issue  is not completely resolved.
The results of the present study indicate the tangible option
to  treat highly-experienced HIV-infected patients in low-  and
middle-income countries. However, this study presents some
limitations.  First, although the observational nature of this
study  precludes some conclusive results, our study included
all  consecutive HIV-infected adults who received at least one
pill  of DRV and the analysis of virologic efﬁcacy considered
non-completers as failures. Second, these results cannot be
necessarily  extrapolated to other settings. Our  patients were
treated  in an urban teaching center of a country with a well-
structured National Program of AIDS, including a free and
universal  access to ART and a network of laboratories to per-
form  CD4 cell count, HIV-1 viral load, and genotyping. Third,
patients  of the present study were  included in the ﬁrst months
of  availability of DRV and raltegravir in our city. This factor can
explain,  at least in part, the high frequency of sensitivity to
these  drugs and the consequent high efﬁcacy in our patients.
A  longer period of inclusion could allow a higher number of
patients  but particularly a more  heterogeneous population,
including cases with more  resistance virus and patients with
less  therapeutic options. Future studies will be important to
assess  the potential relation among temporal trends and the
value  of salvage regimen in our setting.
In conclusion, DRV/r plus OBT was highly effective and
well-tolerated in highly antiretroviral-experienced patients,
under  clinical routine conditions, similar to reported in high-
income  countries. Strong and structured National Programs
and  continued international efforts are necessary in the ongo-
ing  success of access to HIV care strategies in low-  and
middle-income countries, particularly provision of third or
higher-line  of HAART.
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